Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 3/20 | 0.51 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | PYGL | P06737 | 8/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7752057 | 1.00 | MMP8 (0.51) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL7753072 | 0.97 | MMP9 (0.52) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL6890766 | 0.97 | MMP9 (0.52) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL7752030 | 0.92 | MMP9 (0.54) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL6897320 | 0.92 | MMP9 (0.54) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL6894662 | 0.87 | MMP9 (0.47) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL6898216 | 0.85 | MMP9 (0.47) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL7748123 | 0.85 | MMP9 (0.51) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL6895678 | 0.85 | MMP9 (0.51) | MMP8MMP9MMP14MMEACE | |
| SCHEMBL6891245 | 0.83 | MMP9 (0.49) | MMP8MMP9MMP14MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | MMP8 3131/4885MMP9 3772/4885MMP14 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.